Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation by Kenworthy, Rachael et al.
Short-hairpin RNAs delivered by lentiviral vector
transduction trigger RIG-I-mediated IFN activation
Rachael Kenworthy
1, Diana Lambert
1, Feng Yang
1, Nan Wang
2, Zihong Chen
3,
Haizhen Zhu
4, Fanxiu Zhu
1, Chen Liu
4, Kui Li
2 and Hengli Tang
1,*
1Department of Biological Science, Florida State University, Tallahassee, FL 32306-4295,
2Department of
Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163,
3Department of
Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555 and
4Department
of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32611, USA
Received May 15, 2009; Revised August 13, 2009; Accepted August 14, 2009
ABSTRACT
Activation of the type I interferon (IFN) pathway by
small interfering RNA (siRNA) is a major contributor
to the off-target effects of RNA interference in
mammalian cells. While IFN induction complicates
gene function studies, immunostimulation by
siRNAs may be beneficial in certain therapeutic
settings. Various forms of siRNA, meeting different
compositional and structural requirements, have
been reported to trigger IFN activation. The
consensus is that intracellularly expressed short-
hairpin RNAs (shRNAs) are less prone to IFN
activation because they are not detected by
the cell-surface receptors. In particular, lentiviral
vector-mediated transduction of shRNAs has been
reported to avoid IFN response. Here we identify
a shRNA that potently activates the IFN pathway in
human cells in a sequence- and 50-triphosphate-
dependent manner. In addition to suppressing its
intended mRNA target, expression of the shRNA
results in dimerization of interferon regulatory
factor-3, activation of IFN promoters and secretion
of biologically active IFNs into the extracellular
medium. Delivery by lentiviral vector transduction
did not avoid IFN activation by this and another,
unrelated shRNA. We also demonstrated that
retinoic-acid-inducible gene I, and not melanoma
differentiation associated gene 5 or toll-like recep-
tor 3, is the cytoplasmic sensor for intracellularly
expressed shRNAs that trigger IFN activation.
INTRODUCTION
A speciﬁc double-stranded RNA (dsRNA) structure,
 21–22bp dsRNA with 30 overhangs, plays a critical
role in initiating both microRNA (miRNA)- and small
interfering RNA (siRNA)-mediated gene silencing, as it
is the structure recognized by the RNA interference
(RNAi) machinery, the RNA-induced silencing complex
(RISC) (1–3). Except for preformed siRNA duplexes of
 21bp, the RISC-loaded small RNAs are generated by a
ribonuclease (RNase) III-like enzyme that is found in
virtually all eukaryotic organisms. This enzyme, aptly
named Dicer for its ability to cleave a variety of larger
(>30bp) dsRNA molecules into the  21bp dsRNA with
a characteristic 30 overhang of 2nt, is a multidomain
RNA-binding protein and itself a component of RISC.
The primary sequence of the RNAs is not important in
RISC formation, and RNAi can suppress virtually any
target as long as rules of sequence complementarities
between the small RNA and the target RNA are satisﬁed.
dsRNAs are also a type of pathogen-associated
molecular pattern (PAMP) that are detected by cellular
innate immunity sensors named Pattern Recognition
Receptors (PRRs) (4). The interaction between a PAMP
and a PRR triggers activation of the interferon (IFN)
pathway in mammalian cells, which signiﬁcantly changes
the gene-expression proﬁle in the cells and contributes to
the well-documented oﬀ-target eﬀect of RNAi. IFN
induction is especially problematic in antiviral studies
employing RNAi, where the antiviral eﬀect of IFN must
be distinguished from that of RNAi.
Typical IFN-inducing structure patterns include
dsRNA of certain length, single-stranded RNA (ssRNA)
containing 50-triphosphates (50-ppp), the dsRNA analogue
polyinosinic-polycytidylic acid (poly I:C), and certain
dsDNA molecules. These RNA patterns are generally
believed to possess ‘non-self’ properties to allow the cell
to recognize foreign (often viral) RNAs speciﬁcally.
Various forms of siRNA duplexes have been reported to
trigger IFN induction both in vitro and in vivo (5–9),
probably through the cell surface- and/or endosome-
expressed Toll-like receptors (TLRs), including TLR3
and TLR7 (6,8,9).
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plasmid have also been shown to activate IFN (10). The
double-stranded form of these RNAs is below the size
limit of the stem-loop RNAs that can be detected by
the RNA-activated protein kinase (PKR) (11) and is
probably detected by other cytoplasmic PRRs. Two
cytoplasmic RNA helicases, retinoic-acid-inducible gene
I (RIG-I) and melanoma diﬀerentiation associated
gene 5 (MDA5), signal to the IFN-b promoter when
activated by speciﬁc RNA structures (12–14). Although
both PRRs signal through the mitochondrial antiviral
signaling protein MAVS/Cardif/VISA/IPS-1 (15–18),
studies of ligand speciﬁcity suggest that RIG-I and
MDA5 are parallel sensors with overlapping substrates.
For example, although both PRRs are activated by poly
I:C in cell culture systems (12,19–23), MDA5 appears to
be more important in mediating the poly I:C response in
vivo (13,14). In addition, RIG-I can bind and respond to
ssRNAs bearing 50-ppp, whereas MDA5 is not activated
by 50-ppp–containing RNA (24,25). Finally, several
cytosolic sensors for dsDNA has been recently reported
(26–31). Nevertheless, current data on what constitutes
eﬀective substrates for either PRR are incomplete and
sometimes controversial. Here we report for the ﬁrst
time that shRNAs delivered by lentiviral transduction
triggered IFN activation and that RIG-I and MAVS,
but not MDA5 or TLR3, mediated the IFN activation
triggered by intracellularly expressed shRNA, which
could activate both IFN-a and IFN-b promoters. IFN
activation depended on sequence, a 50-ppp and correct
processing of the RNA hairpin by Dicer; it was
independent of promoter choice, presence of blunt ends,
route of delivery and RNAi potency.
MATERIALS AND METHODS
Cells, antibodies and RNAs
GS5 and LH86 cells have been described earlier (32,33).
Huh-7 and 293FT cells were maintained in DMEM supple-
mented with 10% FBS. We used the following antibodies:
anti-CyPA (Biomol, Plymouth Meeting, PA, USA); anti-
CyPB (AfEnity BioReagents, Rockford, IL, USA); anti-
Ku80, anti-Flag and anti-actin (Sigma-Aldrich, St Louis,
MO, USA); anti-IFN stimulate gene (ISG)15 (Rockland
Immunochemicals, Gilbertsville, PA, USA); anti-NS5A
(Virogen, Watertown, MA, USA) and anti-NS3
(in-house). GSB1 and H801 cells have been described
earlier (34). Poly I:C was purchased from Sigma-Aldrich,
and synthetic hairpin RNA was purchased from Integrated
DNA Technologies (Coralville, IA, USA). Synthetic
siRNA was purchased from Ambion (Austin, TX, USA).
Gel electrophoresis and western blotting
Protein contents of cell lysate were quantiﬁed with the
Bio-Rad DC protein assay (Bio-Rad, Hercules, CA,
USA), and an equal amount of total protein was loaded
in each lane. Samples for IRF-3 dimerization assay were
run on a polyacrylamide gel under non-denaturing
conditions (35). Other samples were denatured and
separated by sodium dodecyl sulfate polyacrylamide
gelelectrophoresis (SDS–PAGE). Proteins were then
transferred onto a nitrocellulose membrane and stained
with the appropriate antibodies with the SNAP i.d.
TM
system (Millipore, Worcester, MA, USA) according to
the manufacturer’s instructions.
Transfections
For luciferase assays, cells were seeded to a conﬂuency
of 50%, and for all other assays, cells were seeded to
a conﬂuency of 30%. The next day, transfections of
DNA plasmids and synthetic RNAs were performed
with Lipofectamine
TM 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Plasmids
Plasmids pGL3-IFNA1, pGL3-IFNB, pRL-TK, pCMV-
Flag-IRF-3 and pCR3.1-IRF-7A have been described
earlier (36). shRNAs were expressed from a human
immunodeEciency virus (HIV)-based lentiviral vector
(32,37), and sh-PCAF was constructed on the basis of a
previously reported sequence (38). Plasmid sh-B971/H1
was constructed by cloning of the DNA fragment
encoding the sh-B971 RNA into pSilencer 3.0-H1
(Ambion, Austin, TX, USA) according to the manu-
facturer’s instructions. The RIG-I and TLR3 constructs
have been described (39,40). The RIG-I C construct
encodes Flag-tagged, C-terminal 707 aa of human RIG-I
cloned into a bicistronic expression vector modiﬁed from
pBICEP-CMV-1 (Sigma-Aldrich, St Louis, MO, USA), in
which the CMV promoter was replaced with the
elongation-factor-1 promoter. The MDA5, MDA5-C
constructs were kindly provided by Fujita (12). HCV
genotype 2a NS3-4A protease was expressed from the
pCMV-3Tag-1a plasmid (Stratagene, La Jolla, CA, USA).
Luciferase assay for Interferon promoter activity
293FT cells were seeded in 24-well plates and were
transfected 16h later with 400ng of a shRNA expression
vector, 40ng of pGL3-IFNA1 or pGL3-IFNB, 20ng of
pRL-TK and 50ng of pCR3.1-IRF-7A. Cells were
collected 48h after transfection. Luciferase assays were
performed with the Dual-Glo Luciferase Assay system
reagents (Promega, Madison, WI) and luminescence
quantiﬁed with a Modulus Microplate reader (Turner
BioSystems, Sunnyvale, CA, USA). Ratios of ﬁreﬂy
luciferase (from the pGL3 vectors) to Renilla luciferase
(from the pRL-TK vector) were calculated, and that of
the sh-B971 sample was normalized to 100%.
Lentiviral vectors
Sequences of shRNA are shown in Table 1. Lentiviral
vector production and transduction were performed as
described earlier (37). Viral vectors were pelleted by
ultracentrifugation at 50000g at 4 C for 3h and
resuspended in a volume of PBS that was 1% of the
original medium volume. The titers of the concentrated
vectors were then measured with a p24 ELISA kit
(ZeptoMetrix, Buﬀalo, NY, USA).
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Real-time reverse transcription PCR (RT–PCR) was
performed as described earlier (32). The primers used
were OAS1 forward, 50-AGG TGG TAA AGG GTG
GCT CC-30 and OAS1 reverse 50-ACA ACC AGG TCA
GCG TCA GAT-30; RIG-I forward 50-GAG GCA GAG
GAA GAG CAA GAG G-30 and RIG-I reverse 50-CGC
CTT CAG ACA TGG GAC GAA G-30; GAPDH
forward 50-TCA CTG CCA CCC AGA AGA CTG-30
and GAPDH reverse 50-GGA TGA CCT TGC CCA
CAG C-30. The primers for HCV detection were 50-CGC
TCA ATG CCT GGA GAT TTG-30 and 50-GCA CTC
GCA AGC ACC CTA TC-30.
Flow cytometry
For ﬂow cytometry, GS5 cells were ﬁxed 48h after
treatment in a solution of 2% paraformaldehyde and
analyzed with a FACSCanto ﬂow cytometer (BD
Biosciences, San Jose, CA, USA). Mean GFP intensity
was plotted, and that of the sh-NTC sample was
normalized to 100%.
RNA extraction and northern blots
Total RNA from transiently transfected 293FT cells was
extracted with RNA STAT-60 (Tel-Test, Friendswood,
TX, USA) and separated on a 7.5% urea polyacrylamide
gel. The transfer of RNA onto nitrocellulose membrane
and hybridization were performed according to standard
molecular biology protocols. The probe for detecting the
expressionofsh-B971anditsvariantswasasyntheticDNA
oligomer corresponding to the bottom strand of sh-B971.
Radioactive labeling of the probe was performed with
an end-labeling protocol with T7 polynucleotide kinase
(Ambion, Austin, TX, USA). The exposure and detection
of the radioactive signal was performed with a Typhoon
Imager (GE Healthcare, Piscataway, NJ, USA) with
Quantity One software (Bio-Rad, Hercules, CA, USA).
RESULTS
A short-hairpin RNA directed at CyPB induces IFN
production in human embryonic kidney cells
To investigate the potential role of the cyclophilins (CyPs)
in HCV replication (41), we delivered several shRNAs
directed at mRNAs of three CyPs into HCV replicon
cells by means of a lentiviral vector, using a murine
U6 promoter to drive the expression of the shRNA
(Figure 1A) (37). We observed a discrepancy between
two anti-CyPB shRNAs (B971 and B710) in their
relative eﬃciency in knocking down CyPB expression
and in suppressing HCV. Lentiviral vector sh-B971 was
less eﬃcient in knocking down CyPB expression but
potently inhibited HCV NS5A expression in a human
hepatoma cell line containing replicating HCV RNA
(Figure 1B, left). Viral inhibition was independent of
CyPB knockdown, as control medium from transfected
293FT cells that did not contain any lentiviral vector
particles, generated by omission of the packaging
plasmids during transfection, also inhibited HCV
replication (Figure 1B, right) without aﬀecting CyPB
expression. The fast kinetics of viral inhibition (complete
inhibition with 48h, data not shown) was also more con-
sistent with IFN than with RNAi-based inhibition. The
presence of IFN in the lentiviral vector preparation of
sh-B971 was conﬁrmed by strong induction of 20-50-oligo-
adenylate synthetase 1 (OAS1), a classic IFN-induced
gene, in both naı¨ve Huh-7 and the HCV replicon cell
line (GS5) treated with the medium (Figure 1C). In
addition, HCV replication in an IFN-resistant HCV
replicon cell line (H801), in contrast to that in a wild-
type replicon cell line (GSB1) (34), was not inhibited by
the sh-B971 medium (Figure 1D), suggesting the lack of
additional viral inhibiting agents in the sh-B971 medium.
Expression of sh-B971 in 293FT cells also induced
dimerization of IRF-3, conﬁrming the activation of the
IFN production pathway in these transfected cells
(Figure 1E). Finally, sh-B971 was able to activate both
IFN-a and IFN-b promoters, although the activation
of the IFN-a promoter required coexpression of IRF-7,
which is normally expressed at very low levels in 293-based
cells (Figure 1F). These results demonstrate that sh-B971
is a potent activator of IRF-3 and IRF-7, master
regulators of IFN expression in human cells.
RIG-I mediates the IFN induction by sh-B971
We next investigated the role of the diﬀerent viral/
exogenous RNA sensors, RIG-I, MDA5 and TLR3,
in sh-B971–triggered IFN production. Mammalian
expression plasmids encoding each of these proteins, as
well as the dominant negative (DN) mutants of RIG-I
and MDA5, were transfected into 293FT cells with
shRNAs and an IFN-b promoter reporter construct.
The signaling to IFN-b promoter and the expression of
the PRR proteins were then examined 48h after
transfection. In the absence of sensor proteins, the sh-
B971 increased activation of the IFN-b promoter by
2.6-fold (Figure 2A). Coexpression of MDA5 or TLR3
did not increase or decrease sh-B971’s ability to activate
IFN-b promoter relatively to the negative control shRNA
(sh-NTC), but in the presence of RIG-I coexpression, the
induction of IFN-b promoter by sh-B971 was increased to
 30-fold. Moreover, ectopic expression of a DN mutant
of RIG-I (RIG-I C), but not that of MDA5 (MDA5-C),
completely abrogated IFN promoter activation by
sh-B971. With the exception of TLR3, which required
prolonged exposure of the western blot to be detected,
the cytoplasmic sensors and their mutants were expressed
at comparable levels (Figure 2B). Moreover, activation of
IRF-3 (Figure 1E) and IFN promoters (Figure 1F) in
293FT cells, which do not contain a functional TLR3
signaling pathway (42), indicates that TLR3 plays a
negligible role, if any, in IFN induction by sh-B971.
The combination of sh-B971 and RIG-I produced the
highest level of IFN-b promoter activity, which were
conﬁrmed by western blotting showing that endogenous
ISG15 induction was only detectable in cells cotransfected
with sh-B971 and wild-type RIG-I (Figure 2B). To
conﬁrm further that biologically active IFN was released
from these cells, we applied the culture medium of the
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in which NS5A-GFP expression is used for monitoring
viral RNA replication (43). HCV replication in this cell
line is extremely sensitive to IFN, and the eﬀect of the
cytokine can be readily measured as the change in the
mean GFP intensity of the treated cells. As shown in
Figure 2C, culture medium from sh-B971 eﬃciently
suppressed HCV replication, resulting in a decrease in
Figure 1. A small-hairpin RNA directed at CyPB induces IFN production in human embryonic kidney cells. (A) Sequence of sh-B971, which was
expressed from a self-inactivating human immunodeﬁciency virus (HIV) vector with a murine U6 promoter (59). (B) Inhibition of HCV expression by
culture media of sh-B971-transfected 293FT cells. GS5 cells were treated with culture supernatant taken from 293FT cells transfected with various
shRNA plasmids with (left) or without (right) the packaging plasmids overnight. Cells were then cultured in fresh media for an additional 6 days
before being lysed for western blotting. (C) OAS1 induction by culture supernatant from 293FT cells transfected with sh-B971. Huh 7 and GS5 cells
were treated with culture supernatant from 293FT cells transfected with either sh-Luc or sh-B971 for 24h before RNA extraction and real-time RT–
PCR analysis. OAS1 RNA level was normalized to that of GAPDH RNA. (D) Transfected culture media failed to suppress HCV replication in an
IFN-resistant cell line. HCV replicon cells were cultured as described earlier (34) and then treated with the indicated culture medium from transfected
293FT cells. HCV RNA was analyzed with real-time RT–PCR. (E) IRF-3 dimerization in response to sh-B971 expression. Flag-IRF-3 was
cotransfected with a shRNA into 293FT cells. Cells were lysed 24h after transfection, and total cell lysate was separated on a polyacrylamide
gel under non-denaturing conditions, transferred and stained with an anti-ﬂag antibody. (F) IFN-a and IFN-b promoter activation by sh-B971
expression. Sh-NTC, sh-C454 (an shRNA directed at CyPC), or sh-B971 was cotransfected along with luciferase reporter plasmids with or without
IRF-7. The ratios of ﬁreﬂy luciferase readings to Renilla luciferase readings were plotted.
6590 Nucleic Acids Research, 2009,Vol.37, No. 19the NS5A-GFP intensity within 48h of treatment.
Cotransfecting wild-type RIG-I produced a medium
with stronger inhibition, whereas the RIG-C drastically
suppressed the antiviral eﬀect of the medium. Finally,
real-time RT–PCR analysis revealed that sh-B971, but
not the negative control shRNA, strongly activated
expression of endogenous RIG-I, a well-characterized
ISG whose induction requires paracrine/autocrine action
of IFN (44,45). As expected, poly I:C activated RIG-I
expression in the same assay (Figure 2D). These results,
taken together, show that RIG-I is the cellular sensor that
mediates the IFN induction by sh-B971.
Structure and sequence determinants of shRNA-mediated
IFN activation
The majority of the shRNAs that we use in the lab do not
activate RIG-I expression and IFN signaling despite
having essentially the same structure as sh-B971, so we
wanted to determine whether the sequence of sh-B971
is distinctive enough to trigger the production of IFN.
We ﬁrst tested a synthetic siRNA duplex with the same
target sequence as sh-B971. This siRNA (si-B971-syn)
should resemble the ﬁnal Dicer product of sh-B971
except for the 50-ends. The synthetic siRNA contains
50-OH groups, whereas the Dicer products probably
Figure 2. Sh-B971 acts through the RIG-I pathway to trigger IFN activation. (A) RIG-I, and not melanoma diﬀerentiation associated gene 5
(MDA5) or toll-like receptor 3 (TLR3), mediated IFN induction by sh-B971. Various PRRs and their mutant proteins were coexpressed with either
sh-NTC or sh-B971 along with the luciferase reporters. The ﬁreﬂy luciferase readings were normalized to Renilla luciferase readings, and the value of
sh-B971 was set to 100. (B) Proper expression of the transfected PRR proteins and induction of ISG 15 expression when sh-B971 was coexpressed
with RIG-I. RIG-I, RIG-I C, MDA5 and MDA5 C are all tagged with two tandem copies of Flag epitope. TLR3 is tagged with single Flag epitope
and required prolonged exposure for detection. (C) A dominant negative mutant of RIG-I blocked sh-B971-triggered IFN production. ShRNAs were
cotransfected with either RIG-I or a dominant negative form of RIG-I (RIG-I C) into 293FT cells. The culture supernatant was then tested for its
ability to suppress NS5A-GFP expression in GS5 cells with an overnight treatment. (D) Upregulation of RIG-I RNA level by sh-B971 expression.
293FT cells were transfected with sh-NTC, sh-B971 or polyinosinic-polycytidylic acid. RNA was extracted 24h after transfection and analyzed by
real-time RT PCR. The RIG-I RNA levels were normalized to those of GAPDH RNA.
Nucleic Acids Research, 2009,Vol.37, No. 19 6591contain a 50-monophosphate on one strand and a
50-triphosphate on the other. Si-B971-syn knocked down
CyPB expression as eﬃciently as sh-B971 (Figure 3A)
while failing to activate IFN production, as measured by
the GFP-HCV assay (Figure 3B). To determine whether
the sequence of the intact hairpin RNA before Dicer
cleavage is suﬃcient to trigger IFN, we tested a synthetic
shRNA (sh-B971-syn) that had exactly the same sequence
as the predicted intracellular sh-B971 transcript generated
by the U6 promoter. Again, the 50-end of the synthetic
sh-B971 had a 50-OH group instead of any phosphate.
Sh-B971-syn behaved similarly to si-B971-syn in that it
knocked down CyPB expression without activating
IFN response (Figure 3). These results suggest that the
50-end status of sh-B971 is important for IFN activation,
consistent with the previously ﬁnding that a
50-triphosphate is required for RIG-I activation (24,25).
To determine the contribution of the individual residues
of the sh-B971 sequence, we introduced a series of
point mutations into the shRNA and tested them for
IFN induction. We changed the ﬁrst nucleotide from
A to G, C, or T while maintaining base-pairing between
nucleotides +1 and +47. These mutant shRNAs lacked
the ability to activate IFN production (Table 1). Changing
the +1 nucleotide to G while leaving the +47 nucleotide
intact also abolished IFN activation by the shRNA
(A1/G), as did the reciprocal mutation U47/C. The
importance of the ﬁrst nucleotide was further conﬁrmed
by the inability of sh-B971+1 to activate IFN. The target
of sh-B971+1 was shifted 1nt downstream on the CyPB
mRNA, producing an shRNA starting with a G at the +1
position. The presence of an A at the +1 position was not,
however, suﬃcient to render a shRNA competent for IFN
activation, as replacing the ﬁrst nucleotide of the sh-NTC
with an A did not generate an IFN-inducing shRNA
(NTC-A and NTC+1). These results indicate that a
protruding/unpaired A at the end of the hairpin or the
RNA duplex, a potential result of ‘breathing’ at the end
of the dsRNA, is not suﬃcient to trigger IFN induction as
previously suggested (38).
Two point mutations located farther into the stem
structure of the shRNA (9G9 and B18A1) also reduced
its ability to induce IFN even though the base-pairing was
perfectly maintained in these mutants. Finally, replacing
the 9-nt hairpin loop with a 7-nt loop that had been
previously shown to abolish shRNA-mediated RNAi
(loop A mutant) (46) eliminated sh-B971’s ability to
Figure 3. Structural determinants of IFN activation by sh-B971. 293FT cells were transfected with shRNA-expressing lentiviral plasmids or synthetic
RNAs. (A) Knockdown of CyPB expression by various forms of B971 siRNA. Cells were collected 5 days after transfection and analyzed by western
blot for detection of CyPB. (B) Lack of HCV inhibition by synthetic forms of sh-B971. Culture supernatant from transfected 293FT cells was
collected 48h after transfection and used to treat GS5 cells overnight; the GS5 cells were then analyzed by ﬂow cytometry.
Table 1. Sequence of the siRNA duplexes
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processing in the induction. To determine whether the
inability of the mutant shRNAs to induce IFN was due
to lower expression levels, we performed northern blotting
analysis of the shRNA expression on the wild-type and
two mutants. The mutants A1/G and Loop A were
chosen because their ﬁnal siRNA products have exactly
the same sequence as that of the wild-type sh-B971 and
can thus be detected with the same eﬃciency by the same
probe. Although sh-A/G and sh-Loop A were clearly
unable to activate IFN-b promoter (Figure 4A), they
were both expressed at levels comparable to those of the
wild-type sh-B971 product (Figure 4B). Interestingly, the
ﬁnal siRNA product of sh-Loop A was slightly smaller
than those of sh-B971 and sh-A1/G, suggesting that
cleavage did occur and perhaps occurred one or 2nt into
the stem to compensate for the shorter loop.
RIG-I-mediated IFN induction by sh-B971 is independent
of a blunt end of the dsRNA
Blunt-ended siRNA has been previously reported to be
stronger inducers of IFN than the siRNAs with overhangs
(47). Indeed, a previously reported IFN-inducing shRNA,
sh-PCAF (p300/CREB-binding protein-associated factor),
contains a blunt end (38) and was more potent in
activating IFN than sh-B971 (Figure 5A), which is
predicted to form an overhang of 2–3Ts at each end of
the ﬁnal siRNA. We therefore constructed a version of the
sh-B971 that would be blunt at the end that is not
processed by Dicer by adding two extra As to the 50-end
of the shRNA. This modiﬁcation (Blunt sh-B971) did
not increase the ability of sh-B971 to activate IFN-b
promoter (Figure 5A). We conﬁrmed, in two independent
experiments, that IFN induction by sh-PCAF was also
mediated by RIG-I. First, cotransfection of DN RIG-I
resulted a 50- to 100-fold inhibition of IFN induction by
sh-PCAF (Figure 5B), whereas wild-type RIG-I increased
IFN induction by several fold in the same assay. Second,
when HCV NS3-4A protease, which cleaves MAVS,
thereby blocking the RIG-I pathway, was coexpressed
with either sh-B971 or sh-PCAF, IFN induction by these
shRNAs were severely compromised (Figure 5C), further
substantiating a role of the RIG-I and MAVS pathway
in mediating IFN induction by both the blunt-ended
sh-PCAF and the sh-B971 with overhang. The proper
expression of NS3-4A protease was conﬁrmed by
western blotting (Figure 5D).
Sh-B971 expressed from an H1 promoter triggers IFN
induction
To assess the contribution of the promoter choice in IFN
activation by intracellular expressed shRNA, we expressed
sh-B971 from another commonly used pol III promoter,
the human H1 promoter. Both the original, mU6-driven
sh-B971 and the H1-driven sh-B971 activated IFN-b
promoter (Figure 6A) and resulted in secretion of IFN
into the transfected cell-culture media, which in turn
suppressed HCV replication (Figure 6B). Proper
expression of the siRNA (Figure 6C) and the subsequent
knockdown of CyPB expression (Figure 6D) all appeared
normal for sh-B971 expressed from the H1 promoter
plasmid, which has a backbone diﬀerent from that of
our lentiviral vector carrying the mU6 promoter. These
data suggest that IFN induction by sh-B971 is not
restricted to a particular promoter or expression
construct. Further supporting this conclusion was the
observation that the expression cassette by itself,
removed and isolated from the lentiviral plasmid by
restriction digestion, could also activate IFN production
in transfected 293FT cells (data not shown).
ShRNAs delivered via lentiviral transduction trigger IFN
activation in vitro
To this point, all the IFN induction experiments were
done with transient transfection of DNA vectors and it
was possible that certain features of the double-stranded
plasmid DNA are responsible for IFN induction. We ﬁrst
tried to address this point by transfecting just the shRNA-
expressing cassette, generated either by PCR or restriction
enzyme digestion, into 293FT cells and conﬁrming that
these fragments of  200bp were suﬃcient to trigger
IFN induction (Supplementary Figure S1). To deﬁnitively
rule out any contribution by dsDNA, we used a lentiviral
transduction system which has been suggested to express
shRNAs that can escape detection by PRRs and IFN
activation (48). We produced lentiviral particles
containing shRNAs from 293FT cells using standard
Figure 4. Comparably expressed mutant forms of sh-B971 do not
induce IFN. (A) IFN activation by select sh-B971 mutants. The
shRNA expression plasmids were transfected into 293FT cells with
the luciferase reporters to measure IFN-b promoter activation. The
ﬁreﬂy luciferase readings were normalized to Renilla luciferase
readings, and the value of sh-B971 was set to 100. (B) Intracellular
levels of siRNA products of sh-B971 and mutants. RNA was extracted
from transfected 293FT cells and analyzed by northern blotting with a
DNA oligonucleotide probe that is complementary to all three forms of
sh-B971 (wt, sh-A1/G and Loop A).
Nucleic Acids Research, 2009,Vol.37, No. 19 6593Figure 5. RIG-I mediated IFN induction by shRNA is independent of a blunt end of the dsRNA. (A) IFN-b activation in response to blunt-ended
shRNAs. Both sh-PCAF and Blunt sh-B971 contained two extra As at the 50-end of the shRNA, making the non-hairpin end of the shRNA blunt
rather than having an overhang of two TTs. (B) RIG-I dependency of IFN-b activation by sh-PCAF. (C) Blockade of shRNAs-triggered IFN
activation by HCV NS3-4A. A mammalian expression plasmid encoding the NS3-4A protease from HCV isolate JFH-1 was cotransfected with the
shRNA and luciferase reporter plasmids. (D) Western blot showing expression of HCV NS3-4A in transfected 293FT cells. Cell lysate from (C) was
separated by SDS–PAGE and probed with an anti-NS3 antibody.
Figure 6. Sh-B971 expressed from an H1 promoter triggers IFN activation. Sh-B971 expressed from an H1 promoter was capable of (A) activating
IFN-b promoter and (B) triggering IFN production to inhibit HCV replication in GS5 cells. (C) Intracellular levels of U6- and H1-driven sh-B971
products. RNA extraction and northern blotting were performed as described in Figure 4B. (D) Knockdown of CyPB expression by sh-B971
expressed from an H1 promoter.
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the IFN-containing media, and then used them to infect
naı¨ve 293FT cells (Figure 7A). Both sh-B971 and
sh-PCAF vectors induced IFN production when delivered
as concentrated lentiviral particles, measured both by
HCV suppression (Figure 7B) and by OAS induction
(Figure 7C) in Huh-7 cells. To rule out the possibility
that residual IFN in the concentrated viral particles was
responsible for these results, we added 100U/ml
IFN to the negative control vector sample before the
Figure 7. ShRNAs delivered by lentiviral transduction trigger IFN activation in vitro.( A) Diagram of the experimental setup. Lentiviral vectors were
concentrated by ultracentrifugation for removal of soluble IFN proteins in the vectors prepared from transfected 293FT cells. (B) Transduction of
293FT cells with the concentrated shRNA vectors triggered IFN production. Culture supernatant was collected 48h after transduction and was used
to treat GS5 cells overnight; the GS5 cells were then analyzed 48h after treatment by ﬂow cytometry. (C) OAS induction in Huh 7 cells treated with
culture supernatant from lentivirally transduced cells. Huh 7 cells were treated with culture supernatant for 24h before RNA extraction and RT-PCR
analysis. OAS1 expression level was normalized to that of GAPDH RNA. (D) Knockdown of CyPB expression in transduced cells, which were
collected 5 days after transduction for western blotting. (E) Blockade of lentivirus-triggered IFN activation by a HIV reverse transcriptase inhibitor.
293FT cells were transduced in the presence of 80nM of Nevirapine; culture supernatant was collected 48h after transduction and used to treat GS5
cells. (F) Culture medium from LH86 cells transduced with sh-PCAF suppressed HCV replication. This experiment was done as depicted in (A) with
the LH86 cells in the place of 293FT cells in the transduction step.
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sh-NTC*, was not able to trigger IFN production in
naı¨ve 293FT cells, suggesting that the concentration step
eﬀectively removed the soluble IFN from the viral particle
pellet. Proper knockdown of the siRNA target of sh-B971
was conﬁrmed by this route of shRNA delivery (Figure
7D). To prove deﬁnitively that IFN induction by the
shRNAs was mediated by the lentiviral infection route,
we tested the eﬀect of an inhibitor of HIV reverse
transcriptase, Nevirapine, on IFN induction by sh-B971
and sh-PCAF. As shown in Figure 7E, inclusion of
Nevirapine at the time of transduction eﬀectively
blocked the ability of both shRNAs to induce IFN in
the transduced cells, suggesting the importance of the
reverse transcription step in the expression of the
shRNAs delivered by the lentiviruses. To determine
whether lentiviral vector-delivered shRNA can trigger
IFN induction in cells other than 293FT cells, we
transduced a human hepatoma cell line, LH86, which
has been reported to produce IFN upon viral infection
(33), and examined IFN induction in these cells. Culture
medium from LH86 cells transduced with sh-PCAF
contained biologically active IFN, which suppressed
HCV replication in GS5 cells (Figure 7F), indicating
that the ability of shRNAs delivered by lentivirus to
induce IFN response was not limited to 293FT cells.
DISCUSSION
It has been reported that certain chemically synthesized
and phage polymerase in vitro transcribed siRNAs can
non-speciﬁcally induce IFN responses and produce oﬀ-
target eﬀect via various PRRs, including TLRs.
However, the induction of IFN response by shRNAs
and its underlying mechanisms have not been as well
studied. The actual number of shRNAs that are capable
of triggering IFN response will certainly be larger than the
few that have been reported in the literature, yet very little
is known about the unique characteristics of the select
shRNAs and the pathway that they use to activate IFN
production. The present study identiﬁes RIG-I, but not
MDA5 or TLR3, as the mediator for activation of IFN
responses by two shRNAs that are distinct in sequence
and structure but both capable of IFN induction in
human cells. This was demonstrated by induction of
IRF-3 dimerization, activation of IFN promoters,
induction of endogenous ISGs (ISG15, OAS and
RIG-I), and secretion of IFN, all of which depended on
RIG-I and its downstream adaptor, MAVS. In addition,
we show that delivery of these shRNAs via lentiviral
transduction does not reduce their IFN-inducing
capacity, indicating that the ability of lentiviral vector
transduction to avoid IFN induction by shRNAs, as
reported previously (48), may not be universally
applicable to all the shRNAs.
Speciﬁc recognition of dsRNAs or ssRNAs bearing
50-triphosphates by RIG-I is presumably determined
mostly by structural features other than the nucleotide
sequence of the RNA. Yet IFN activation by sh-B971
exhibited a stringent dependence on speciﬁc nucleotides
at multiple positions of the shRNA. An AA dinucleotide
at the beginning of the U6 transcript has previously been
suggested to result in aberrant transcription, and
preserving a C/G sequence at positions  1/+1 suggested
to avert IFN induction (38). We indeed observed a strict
requirement for an adenylate at the +1 position of sh-
B971 for RIG-I recognition and IFN activation, but we
observed no diﬀerence in expression levels or the apparent
sizes of the sh-B971 RNAs bearing either an A or a G at
the +1 position. Furthermore, mutations introduced
elsewhere in the shRNA also abolished or diminished
sh-B971’s ability to activate IFN, suggesting additional
sequence requirement for eﬃcient RIG-I recognition and
IFN triggering. Despite these results, because we were
not successfully in cloning and sequencing the vector-
expressed siRNA, we cannot exclude the possibility that
the adenylate at the +1 position interferes with
transcription and that the resultant abnormal transcript
contributes to IFN induction.
Interestingly, the loop A mutant, which contains a
predicted loop of 7nt, generated a siRNA duplex inside
the cells that is slightly smaller than that of the shRNAs
with a wild-type hairpin loop, suggesting the processing by
Dicer into the stem, perhaps fulﬁlling the requirement of a
length of 9nt for the hairpin loop (46). This mutant form
of sh-B971 was not, however, able to trigger IFN
activation.
Despite the abilities of both sh-B971 and sh-PCAF to
activate the RIG-I pathway, the two shRNAs are
unrelated in sequence. Two short stretches of siRNA
sequences, GUCCUUCCAA and UGUGU, that have
been previously deﬁned as IFN- or cytokine-activating
motifs (8,9) are not found in either sh-B971 or sh-
PCAF. Any common sequence motifs of IFN-activating
shRNAs, if any, remain to be deﬁned. The two shRNAs
also diﬀer in that one is predicted to contain one blunt end
and the other two ends with overhangs. These results
suggest that, although blunt ends may increase siRNA’s
ability to be recognized by RIG-I (47), they are not
required for IFN activation by an endogenously expressed
shRNA. The best-characterized RNA structure motif
recognized by RIG-I is the 50-ppp, which is absent from
virtually all the cellular RNAs as a result of either
50-capping or internal cleavage before their appearance
in the cytoplasm. A synthetic shRNA that has the same
sequence as sh-B971 but lacks the 50-ppp failed to induce
IFN, suggesting the 50-end status of the intracellularly
expressed sh-B971 contributes to IFN activation.
Whether or not the 50-end of an shRNA is capped has
not been investigated. Murine U6 RNA does not
contain the trimethylguanosine cap that is present on
mRNAs and other U small nuclear RNAs; instead it
contains a g-monomethyl phosphate cap at its 50-end
(49). Capping of heterologous transcripts produced from
the mU6 promoter, however, requires a stem loop at the
50-end of the transcript and an AUAUAC sequence
immediately after (50). Most shRNAs, including sh-B971
and sh-PCAF, would not meet these requirements and
thus should contain unmodiﬁed 50-ppp. Similarly, no
evidence of a cap structure for H1 transcripts could be
found in the literature. We attempted to express sh-B971
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promoter (51). The primary transcript generated with this
construct would be capped at 50-end by a trimethyl-
guanosine cap and the ﬁnal siRNA duplex would bear a
monophosphate at the 50-ends of both strands because of
Drosha and Dicer cleavage. This version of the sh-B971
vector was much weaker in its ability to trigger IFN
activation. Unfortunately the intracellular expression
of the RNA duplex was also much weaker and barely
detectable by northern blotting. In addition, no knock-
down of the target CyPB mRNA was seen with this
miRNA-based sh-B971 (data not shown). As a result,
whether sh-B971, if expressed at higher level from this
construct, could eﬀectively activate IFN remains unclear.
So far as we know, ours is the ﬁrst report of IFN
activation in the target cells by shRNAs delivered
by lentiviral transduction. A previous report of IFN
induction by lentiviral vector-expressed shRNA only
examined the IFN generated in the vector-producing
cells, which then up-regulated IFN-stimulated genes in
the transduced cells (10). The distinction is important as
lentiviral vectors used in a gene-therapy setting will likely
be puriﬁed and free of any IFN that has been generated
during the vector preparation step, but IFN activation in
the target cells would pose a more serious concern. Our
data suggest the importance of screening shRNAs for IFN
induction in the transduced cells in vitro before large-
scale studies. An HIV reverse transcriptase inhibitor
eﬃciently blocked IFN production by both sh-B971 and
sh-PCAF when delivered by transduction, indicating the
virion-encapsulated RNA was not able to trigger IFN
activation. In this respect, it is interesting to note that
positive-stranded RNA viruses, which produce dsRNA
intermediates in the cytoplasm during replication
(52–55), often replicate in membrane enclosed vesicles
(56), This sequestration of viral dsRNA in membranous
structures may shield the RNA from the cytoplasmic
PRRs and contribute to a successful infection.
IFN-induction and RNAi by shRNAs appear to be
independent functions of the same RNA (57). Our
results also showed that IFN-induction by sh-B971 is
independent of its ability to suppress target mRNA
expression through RNAi. On the other hand, it might
be possible to screen for duel functional siRNAs that
confer therapeutic beneﬁts by both RNAi and immuno-
stimulation (58). For example, siRNAs that target either
viral genomes or cellular cofactors of the viruses can be
screened for their ability to trigger IFN activation in hopes
of ﬁnd ‘super siRNAs’ with increased eﬃcacy against
IFN-sensitive viruses.
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